spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  thrombin inhibitor 

 HSMN NewsFeed - 15 Jul 2014
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Biopharmaceuticals Interventional
 HSMN NewsFeed - 12 Dec 2012
The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Aug 2012
Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Feb 2011
Atherotech Diagnostics Lab Taps Mize as Vice President of Regulatory Affairs
Diagnostics Personnel
 HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA
 HSMN NewsFeed - 15 Apr 2010
Comparative Trial of Canyon's Iprivask(R) (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2009
The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 19 Jun 2009
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Feb 2009
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Sep 2008
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 May 2008
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 May 2008
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Mar 2008
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Biopharmaceuticals Neurology Interventional
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Sep 2007
FDA Accepts sNDA for Expanded Use of Angiomax(R) (bivalirudin)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Aug 2007
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Jul 2007
Auriga Laboratories Appoints Lisa Tripodi as Vice President of Trade Relations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jul 2007
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Biopharmaceuticals
 HSMN NewsFeed - 2 Jul 2007
The Medicines Company Reacquires Angiox(R) (Bivalirudin) Rights in Europe from Nycomed
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Jun 2007
Nuvelo Resumes Development of Alfimeprase in Multiple Blood-Clot Related Indications
Biopharmaceuticals
 HSMN NewsFeed - 27 Mar 2007
Nuvelo Receives FDA Fast Track Status for rNAPc2 in Both First- and Second-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2007
ACUITY One-Year Findings Meet All Primary Endpoints in Favor of Angiomax(R) (Bivalirudin) Alone Treatment Group
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Dec 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of Hematology
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Nov 2006
Nuvelo Announces Presentations on Alfimeprase and rNAPc2 at The American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Jun 2006
Nuvelo Announces Completion of Phase 2 Heparin Replacement Trial Evaluating rNAPc2 in Acute Coronary Syndromes
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 43

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 43 additional stories matching:
thrombin inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.